Authors: P. Husa 1; J. Šperl 2; P. Urbánek 3; S. Fraňková 2 Authors‘ workplace: Klinika infekčních chorob LF MU a FN Brno 1; Klinika hepatogastroenterologie IKEM, Praha 2; Interní klinika 1. LF UK a ÚVN – VFN Praha 3 Published in: Gastroent Hepatol 2026; 80(2): 124-143 Category: Hepatology: Best Practises doi: https://doi.org/10.48095/ccgh2026124
The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2017. The base for these guidelines were European Association for the Study of the Liver (EASL) guidelines from May 2025. According to qualified estimates, there are 254 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. HBV infection can cause serious, life-threatening liver damage – fulminant hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). The main goal of treatment is to prolong life and improve its quality by preventing the progression of chronic hepatitis to liver cirrhosis, decompensation of cirrhosis, and the development of HCC. A prerequisite for achieving this goal is sustained suppression of HBV replication. Other treatment goals include preventing vertical transmission of infection from mother to newborn, preventing HBV reactivation, treating extrahepatic manifestations (EHM) of HBV, and reducing the likelihood of HBV transmission between individuals. In general, there are two possible strategies for treating chronic hepatitis B: treatment with nucleos(t)ide analogues (NAs) or pegylated interferon alfa. Currently, the vast majority of patients in the Czech Republic and throughout Europe are treated with NAs. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) should be used as first-line NAs. The main advantage of treatment with highly effective NAs with a high genetic barrier to resistance is predictably high and long-term antiviral efficacy leading to undetectable HBV DNA in serum in the vast majority of adherent patients and the favorable safety profile of these drugs. These NAs can be used to treat any patient with chronic hepatitis B and are the only treatment option for patients with decompensated liver cirrhosis, after liver transplantation, with EHM HBV infection, severe acute hepatitis B, or exacerbation of chronic hepatitis B. When deciding between ETV, TDF, and TAF, it is necessary to assess comorbidities (especially renal insufficiency and bone density reduction) and other factors (women of childbearing age, pregnant women, older age).
chronic hepatitis B – entecavir (ETV) – tenofovir disoproxil fumarate (TDF) – tenofovir alafenamide (TAF)
1. Husa P, Šperl J, Urbánek P et al. Doporučený postup diagnostiky a léčby chronické hepatitidy B. Gastroent Hepatol 2014; 68(6): 514 – 526. doi: 10.14735/ amgh2014514.
2. Husa P, Šperl J, Urbánek P et al. Diagnosis and therapy of chronic hepatitis B: Czech national guidelines. Klin Mikrobiol Infect Lek 2014; 20(4): 121 – 132.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2025; 83(2): 502 – 583. doi: 10.1016/ j.jhep.2025.03.018.
4. WHO. Global hepatitis report 2024: action for accession low - and middle-income countries. 2024 [online]. Dostupné z: https:/ / www.who.int/ publications/ i/ item/ 9789240091672.
5. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol 2023; 8(10): 879 – 907. doi: 10.1016/ S2468-1253(23)00197-8.
6. Němeček V, Částková J, Fritz P et al. The 2001 serological survey in the Czech Republic – viral hepatitis. Cent Eur J Public Health 2003; 47(Suppl 1): S54 – S61.
7. Bílková Fránková H, Kloudová A, Zelená H et al. Víceúčelový sérologický přehled (spalničky, příušnice, pertusse, virová hepatitida B) SP 2013, ČR: závěrečná zpráva, příloha č. 1. Zprávy CEM (SZÚ Praha) 2014; 23 : 1 – 152. 2015 [online]. Dostupné z: http:/ / www.zuusti.cz/ wp-content/ uploads/ 2015/ 04/ SP-2013-vnitřek-do-TISKU.pdf.
8. ISIN. Epidemiologická databáze Státního zdravotního ústavu Praha. 2025 [online]. Dostupné z: http:/ / www.szu.cz/ publikace/ data/ infekce-v-cr.
9. Husa P, Urbánek P. Virová hepatitida B. In: Urbánek P, Brůha R (eds). Hepatologie. Praha: Grada Publishing: 2022 : 343 – 355.
10. Huang DQ, Tran A, Yeh M-L et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology 2023; 78(5): 1558 – 1568. doi: 10.1097/ HEP.0000 000000000459.
11. Lai JC, Wong GL, Tse YK et al. Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis. J Hepatol 2025; 82(6): 992 – 1003. doi: 10.1016/ j.jhep.2024.11.018.
12. Yapali S, Talaat N, Fontana RJ et al. Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol 2015; 13(1): 193.e1 – 201.e1. doi: 10.1016/ j.cgh.2014.07.019.
13. Pronier C, Candotti D, Boizeau L et al. The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection. J Clin Virol 2020; 129 : 104507. doi: 10.1016/ j.jcv.2020.104507.
14. Fu MX, Simmonds P, Andreani J et al. Ultrasensitive PCR system for HBV DNA detection: risk stratification for occult hepatitis B virus infection in English blood donors. J Med Virol 2023; 95(10): e29144. doi: 10.1002/ jmv.29144.
15. Duarte-Rojo A, Taouli B, Leung DH et al. Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline. Hepatology 2025; 81(2): 725 – 748. doi: 10.1097/ HEP.00000000000 00852.
16. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63(3): 743 – 752. doi: 10.1016/ j.jhep.2015.05.022.
17. Papatheodoridi M, Hiriart JB, Lupsor-Platon M et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol 2021; 74(5): 1109 – 1116. doi: 10.1016/ j.jhep.2020.11.050.
18. Cornberg M, Wong VW-S, Locarnini S et al. The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017; 66(2): 398 – 411. doi: 10.1016/ j.jhep.2016.08.009.
19. Kramvis A, Chang KM, Dandri M et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 2022; 19(11): 727 – 745. doi: 10.1038/ s41575-022-00649-z.
20. Yoshida K, Desbiolles A, Feldman SF et al. Hepatitis B core-related antigen to indicate high viral load: systematic review and meta-analysis of 10,397 individual participants. Clin Gastroenterol Hepatol 2021; 19(1): 46 – 60.e8. doi: 10.1016/ j.cgh.2020.04.045.
21. Shimakawa Y, Ndow G, Kaneko A et al. Rapid point-of-care test for hepatitis B core-related antigen to diagnosehigh viral load in resource-limited settings. Clin Gastroenterol Hepatol 2023; 21(7): 1943.e2 – 1946.e2. doi: 10.1016/ j.cgh.2022.05.026.
22. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc 2006; 295(1): 65 – 73. doi: 10.1001/ jama.295.1.65.
23. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130(3): 678 – 686. doi: 10.1053/ j.gastro.2005.11.016.
24. Chen X, Wu F, Liu Y et al. The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta-analyses. Oncotarget 2016; 7(31): 49299 – 49309. doi: 10.18632/ oncotarget.10335.
25. Chen CJ, Yang HI, Iloeje UH et al. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49(Suppl 5): S72 – S84. doi: 10.1002/ hep.22884.
26. Gerlich WH. Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy. Intervirology 2014; 57(3 – 4): 202 – 211. doi: 10.1159/ 000360949.
27. Incident Investigation Teams and Others. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. N Engl J Med 1997; 336(3): 178 – 184. doi: 10.1056/ NEJM199701163360304.
28. Yoo JJ, Jung EA, Kim SG et al. Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis. J Int AIDS Soc 2024; 27(9): e26358. doi: 10.1002/ jia2.26358.
29. Lin S, Huang W, Liao Z et al. Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamideor tenofovir disoproxil fumarate. Sci Rep 2024; 14(1): 27369. doi: 10.1038/ s41598-024-78656-0.
30. Hwang EG, Jung EA, Yoo JJ et al. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hepatol Int 2023; 17(4): 860 – 869. doi: 10.1007/ s12072-023-10528-7.
31. Mallon PWG, Brunet L, Fusco JS et al. Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides. Open Forum Infect Dis 2022; 9(1): ofab621. doi: 10.1093/ ofid/ ofab621.
32. Kanters S, Renaud F, Rangaraj A et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy-a systematic literature review and network meta-analysis. EClinicalMedicine 2022; 48 : 101412. doi: 10.1016/ j.eclinm.2022. 101412.
33. Zoutendijk R, Reijnders JG, Zoulim F et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62(5): 760 – 765. doi: 10.1136/ gutjnl-2012-302024.
34. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137(5): 1593 – 1608. doi: 10.1053/ j.gastro.2009.08.063.
35. Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130(7): 2039 – 2049. doi: 10.1053/ j.gastro.2006.04.007.
36. Kitrinos KM, Corsa A, Liu Y et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59(2): 434 – 442. doi: 10.1002/ hep.26686.
37. Chan HL, Buti M, Lim YS et al. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol 2024; 119(3): 486 – 496. doi: 10.14309/ ajg.0000000000002468.
38. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69(1): 182 – 236. doi: 10.1016/ j.jhep.2018.03.019.
39. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370 – 398. doi: 10.1016/ j.jhep.2017.03.021.
40. Wiegand J, Wedemeyer H, Franke A et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat 2014; 21(10): 744 – 750. doi: 10.1111/ jvh.12210.
41. Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E et al. Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis. Cochrane Database Syst Rev 2017; 3(3): CD011645. doi: 10.1002/ 14651858.CD011645.pub2.
42. Yu JW, Sun LJ, Zhao YH et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55(3): 775 – 783. doi: 10.1007/ s10620-009-1060-5.
43. Brown RS, McMahon BJ, Lok ASF et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology 2016; 63(1): 319 – 333. doi: 10.1002/ hep.28302.
44. Li W, Jia L, Zhao X et al. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol 2018; 18(1): 121. doi: 10.1186/ s12876-018-0847-2.
45. Shang J, Wen Q, Wang CC et al. Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: long-term follow-up. J Viral Hepat 2017; 24(Suppl 1): 43 – 48. doi: 10.1111/ jvh.12785.
46. Zeng QL, Yu ZJ, Ji F et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study. Clin Infect Dis 2021; 73(9): e3324 – e3332. doi: 10.1093/ cid/ ciaa1939.
47. Ding Y, Cao L, Zhu L et al. Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. Aliment Pharmacol Ther 2020; 52(8): 1377 – 1386. doi: 10.1111/ apt.16043.
48. Chen R, Zou J, Long L et al. Safety and efficacy of tenofovir alafenamide fumarate in early-middle pregnancy for mothers with chronic hepatitis B. Front Med (Lausanne) 2021; 8 : 796901. doi: 10.3389/ fmed.2021.796901.
49. Pan CQ, Zhu L, Yu AS et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for preventing vertical transmission in chronic hepatitis B mothers: a systematic review and meta-analysis. Clin Infect Dis 2024; 79(4): 953 – 964. doi: 10.1093/ cid/ ciae288.ciae288.
50. Wen WH, Chang MH, Zhao LL et al. Motherto-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013; 59(1): 24 – 30. doi: 10.1016/ j.jhep.2013.02.015.
51. Pan CQ, Duan ZP, Bhamidimarri KR et al. Analgorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10(5): 452 – 459. doi: 10.1016/ j.cgh.2011.10.041.
52. You H, Wang F, Li T et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol 2023; 11(6): 1425 – 1442. doi: 10.14218/ JCTH.2023.00320.
53. Ehrhardt S, Xie C, Guo N et al. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis 2015; 60(2): 275 – 278. doi: 10.1093/ cid/ ciu798.
54. Hu X, Wang L, Xu F. Guides concerning tenofovir exposure via breastfeeding: a comparison of drug dosages by developmental stage. Int J Infect Dis 2019; 87 : 8 – 12. doi: 10.1016/ j.ijid.2019.07.023.
55. Li S, Jin J, Jiang Y et al. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate. Int J Antimicrob Agents 2023; 61(3): 106726. doi: 10.1016/ j.ijantimicag.2023.106726.
56. Li B, Liu Z, Liu X et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load. Hepatol Int 2021; 15(5): 1103 – 1108. doi: 10.1007/ s12072-021-10235-1.
57. Pan YC, Jia ZF, Wang YQ et al. The role of caesarean section and nonbreastfeeding in preventing mother-to-childtransmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis. J Viral Hepat 2020; 27(10): 1032 – 1043. doi: 10.1111/ jvh.13314.
58. Levy MT, Terrault NA. Caesarean section or non-breastfeeding for prevention of MTCT-beware of sending the wrong message. J Viral Hepat 2021; 28(3): 575 – 576. doi: 10.1111/ jvh.13455.
59. Yang M, Qin Q, Fang Q et al. Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: a meta-analysis. BMC Pregnancy Childbirth 2017; 17(1): 303. doi: 10.1186/ s12884-017-1487-1.
60. Chen HL, Cai JY, Song YP et al. Vaginal delivery and HBV mother to child transmission risk after immunoprophylaxis: a systematic review and a meta-analysis. Midwifery 2019; 74 : 116 – 125. doi: 10.1016/ j.midw.2019.03.024.
61. Pan CQ, Zou HB, Chen Y et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol 2013; 11(10): 1349 – 1355. doi: 10.1016/ j.cgh.2013.04.026.
62. Singal AK, Salameh H, Kuo YF et al. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma inchronic hepatitis B. Aliment Pharmacol Ther 2013; 38(2): 98 – 106. doi: 10.1111/ apt.12344.
63. Shim JH, Lee HC, Kim KM et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52(2): 176 – 182. doi: 10.1016/ j.jhep.2009.11.007.
64. Wang N, He S, Zheng Y et al. Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis. BMC Gastroenterol 2023; 23(1): 388. doi: 10.1186/ s12876-023-03024-7.
65. Li J, Hu C, Chen Y et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis 2021; 21(1): 567. doi: 10.1186/ s12879-021-06237-x.
66. Peng W, Gu H, Cheng D et al. Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-onchronic liver failure: real-world study. Front Microbiol 2023; 14 : 1185492. doi: 10.3389/ fmicb.2023.1185492.
67. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol 2023; 79(2): 433 – 460. doi: 10.1016/ j.jhep.2023.05.00.
68. Husa P. Šperl J, Urbánek P et al. Doporučený postup diagnostiky a léčby chronické hepatitidy D. Datum vydání doporučení. 2023. Vnitr Lek 2023; 69(8): 525 – 532. doi: 10.36290/ vnl.2023.104.
69. Husa P, Šperl J, Urbánek P et al. Doporučený postup diagnostiky a léčby chronické hepatitidy D. Klin Mikrobiol Inf Lek 2024; 29(Suppl 3): 1 – 9.
70. Degasperi E, Anolli MP, Uceda Renteria SC et al. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. J Hepatol 2022; 77(6): 1525 – 1531. doi: 10.1016/ j.jhep.2022.07.016.
71. Dietz-Fricke C, Tacke F, Zöllner C et al. Treating hepatitis D with bulevirtide – real-world experience from 114 patients. JHEP Rep 2023; 5(4): 100686. doi: 10.1016/ j.jhepr.2023.100686.
72. Leumi S, Bigna JJ, Amougou MA et al. Global burden of hepatitis B infection in people living with human immunodeficiency virus: a systematic review and meta-analysis. Clin Infect Dis 2020; 71(11): 2799 – 2806. doi: 10.1093/ cid/ ciz1170.
73. Kim HN, Newcomb CW, Carbonari DM et al. Risk of HCC with hepatitis B viremia among HIV/ HBV-coinfected persons in North America. Hepatology 2021; 74(3): 1190 – 1202. doi: 10.1002/ hep.31839.
74. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75(3): 347 – 354. doi: 10.1002/ (SICI)1097-0215(19980130)75 : 3< 347::aid-ijc4>3.0.co;2-2.
75. Shi J, Zhu L, Liu S et al. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005; 92(3): 607 – 612. doi: 10.1038/ sj.bjc.6602333.
76. Mücke MM, Backus LI, Mücke VT et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2018;3(3): 172 – 180. doi: 10.1016/ S2468-1253(18)30002-5.
77. Serper M, Forde KA, Kaplan DE. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort. J Viral Hepat 2018; 25(2): 187 – 197. doi: 10.1111/ jvh.12784.
78. Jaroszewicz J, Pawłowska M, Simon K et al. Low risk of HBV reactivation in a large European cohort of HCV/ HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther 2020; 18(10): 1045 – 1054. doi: 10.1080/ 14787210.2020.1782189.
79. Papatheodoridis GV, Lekakis V, Voulgaris T et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J Hepatol 2022; 77(6): 1670 – 1689. doi: 10.1016/ j.jhep.2022.07.003.
80. Cholongitas E, Haidich AB, Apostolidou-Kiouti F et al. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol 2018; 31(4): 480 – 490. doi: 10.20524/ aog.2018.0266.
81. Mozessohn L, Chan KK, Feld JJ et al. Hepatitis B reactivation in HBsAg-negative/ HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat 2015; 22(10): 842 – 849. doi: 10.1111/ jvh.12402.
82. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329(25): 1842 – 1847. doi: 10.1056/ NEJM 199312163292503.
83. Duvoux C, Belli LS, Fung J et al. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virusrelated infection before and after liver transplantation. Aliment Pharmacol Ther 2021; 54(5): 583 – 605. doi: 10.1111/ apt. 16374.
84. Fung J, Wong T, Chok K et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years. Hepatology 2017; 66(4): 1036 – 1044. doi: 10.1002/ hep.29191.
85. Agüero F, Forner A, Manzardo C et al. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Hepatology 2016; 63(2): 488 – 498. doi: 10.1002/ hep.28321.
86. Jacob JS, Shaikh A, Goli K et al. Improved survival after liver transplantation for patients with human immunodeficiency virus (HIV) and HIV/ hepatitis C virus coinfection in the integrase strand transfer inhibitor and direct-acting antiviral eras. Clin Infect Dis 2023; 76(4): 592 – 599. doi: 10.1093/ cid/ ciac821.
87. Faria LC, Gigou M, Roque-Afonso AM et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134(7): 1890 – 1899. doi: 10.1053/ j.gastro.2008.02.064.
88. Saab S, Yeganeh M, Nguyen K et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15(11): 1525 – 1534. doi: 10.1002/ lt.21882.
89. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol 2024; 81(6): 1040 – 1086. doi: 10.1016/ j.jhep.2024.07.032.
90. Chancharoenthana W, Townamchai N, Pongpirul K et al. The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study. Am J Transplant 2014; 14(12): 2814 – 2820. doi: 10.1111/ ajt.12921.
91. Hui CK, Lie A, Au WY et al. Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant 2005; 5(6): 1437 – 1445. doi: 10.1111/ j.1600-6143. 2005.00887.x.
92. Wong GL, Hui VW, Yip TC et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther 2022; 56(5): 869 – 877. doi: 10.1111/ apt.17120.
93. Fan W, Chen XF, Shen C et al. Hepatitis B vaccine response in obesity: a meta-analysis. Vaccine 2016; 34(40): 4835 – 4841. doi: 10.1016/ j.vaccine.2016.08.027.
94. Aggeletopoulou I, Davoulou P, Konstantakis C et al. Response to hepatitis B vaccination in patients with livercirrhosis. Rev Med Virol 2017; 27(6). doi: 10.1002/ rmv.1942.
95. Sheffield JS, Hickman A, Tang J et al. Efficacy of an accelerated hepatitis b vaccination program during pregnancy. Obstet Gynecol 2011; 117(5): 1130 – 1135. doi: 10.1097/ AOG. 0b013e3182148efe.
96. A two-dose hepatitis B vaccine for adults (Heplisav-B). JAMA 2018; 319(8): 822 – 823. doi: 10.1001/ jama.2018.1097.
97. Awad AM, Ntoso A, Connaire JJ et al. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. Vaccine 2021; 39(25): 3346 – 3352. doi: 10.1016/ j.vaccine.2021.05.003.
98. Rosman AS, Basu P, Galvin K et al. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997; 103(3): 217 – 222. doi: 10.1016/ s0002-9343(97)00132-0.
99. Gupta A, Fine SM, Vail RM et al. Prevention and management of hepatitis B virus infection in adults with HIV. Baltimore (MD): Johns Hopkins University 2022.
100. Rodríguez-Tajes S, Pocurull A, Lens S et al. Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis. J Viral Hepat 2021; 28(7): 1019 – 1024. doi: 10.1111/ jvh.13509.
101. Amjad W, Alukal J, Zhang T et al. Two-dose hepatitis B vaccine (Heplisav-B) results in better seroconversion than three-dose vaccine (Engerix-B) in chronic liver disease. Dig Dis Sci 2021; 66(6): 2101 – 2106. doi: 10.1007/ s10620-020-06437-6.
102. David MC, Ha SH, Paynter S et al. A systematic review and metaanalysis of management options for adults who respond poorly to hepatitis B vaccination. Vaccine 2015; 33(48): 6564 – 6569. doi: 10.1016/ j.vaccine.2015.09.051.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
